Sunshine Biopharma says K1.1 mRNA shows tumor suppression in liver cancer mouse models

Sunshine Biopharma reported in vivo tumor suppression from its K1.1 mRNA lipid nanoparticle program in orthotopic hepatocellular carcinoma mouse models.

Systemic delivery restored tumor-suppressor expression in grafted liver tumors in a dose-dependent manner; treatment was described as well tolerated.

In vitro results showed antiproliferative activity in several non-small cell lung cancer cell lines.

Next phase targets NSCLC with concurrent K1.1 mRNA delivery alongside a cancer vaccine, aiming to convert “cold” tumors into “hot” tumors.